Polymyxin triple combinations against polymyxin-resistant, multidrug-resistant, KPC-producing Klebsiella pneumoniae

SM Aye, I Galani, H Yu, J Wang, K Chen… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
Resistance to polymyxin antibiotics is increasing. Without new antibiotic classes,
combination therapy is often required. We systematically investigated bacterial killing with …

Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model

SKB Sy, L Zhuang, ME Beaudoin… - Journal of …, 2017 - academic.oup.com
Objectives: This study evaluated the in vitro pharmacodynamics of combinations of
ceftazidime and the non-β-lactam β-lactamase inhibitor, avibactam, against ceftazidime …

New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver …

GG Rao, NS Ly, CE Haas, S Garonzik… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Increasing evidence suggests that colistin monotherapy is suboptimal at currently
recommended doses. We hypothesized that front-loading provides an improved dosing …

Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …

X Liu, C Huang, PJ Bergen, J Li, J Zhang… - Journal of Zhejiang …, 2023 - Springer
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …

[HTML][HTML] In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and …

Y Wang, H Li, X Xie, XH Wu, X Li, Z Zhao, S Luo… - Journal of Global …, 2020 - Elsevier
Objectives Limited therapeutic options exist for treating severe infections caused by
multidrug-resistant (MDR) and extensively drug-resistant Gram-negative bacteria (GNB). In …

Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate

M Hecht, R Veigure, L Couchman, CI S Barker… - Bioanalysis, 2018 - Taylor & Francis
Traditionally, bioanalytical laboratories do not report actual concentrations for samples with
results below the LOQ (BLQ) in pharmacokinetic studies. BLQ values are outside the method …

Optimization of polymyxin B in combination with doripenem to combat mutator Pseudomonas aeruginosa

NS Ly, ZP Bulman, JB Bulitta, C Baron… - Antimicrobial agents …, 2016 - Am Soc Microbiol
Development of spontaneous mutations in Pseudomonas aeruginosa has been associated
with antibiotic failure, leading to high rates of morbidity and mortality. Our objective was to …

Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies

SJ Wallace, RL Nation, J Li, BJ Boyd - Journal of pharmaceutical sciences, 2013 - Elsevier
Remote loading of azithromycin into liposomes, and subsequent release behavior in the
presence of colistin, has been investigated with a view to understand the potential of …

Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems …

S López-Argüello, M Montaner… - Antimicrobial agents …, 2023 - Am Soc Microbiol
The β-lactam antibiotics have been successfully used for decades to combat susceptible
Pseudomonas aeruginosa, which has a notoriously difficult to penetrate outer membrane …

In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model

H Yang, N Lv, L Hu, Y Liu, J Cheng, Y Ye, J Li - Infectious diseases, 2016 - Taylor & Francis
Background: With increasing antibiotic resistance, the selection of effective treatment of A.
baumannii infections is particularly challenging. Methods: This study assessed the activities …